FindTrial
Sign In

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523342-27-00
Enrollment
70
Registered
2026-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia areata

Brief summary

​​Percent change from baseline in the SALT score, at Week 28.

Interventions

DRUGPlacebo for LAD603
DRUGLAD603

Sponsors

Almirall S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
​​Percent change from baseline in the SALT score, at Week 28.—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 26, 2026